MedTrace Logo

Effect of Hydroxytyrosol on NLR, MLR, and SOD in Hypertensive Pregnant Women

NCT07074548 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-01-02

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate whether hydroxytyrosol supplementation (10 mg/day for 4 weeks) is effective in improving inflammatory and oxidative stress markers in pregnant women diagnosed with hypertensive disorders of pregnancy (including preeclampsia, chronic hypertension, and gestational hypertension). The main questions it aims to answer are:

1. Does hydroxytyrosol supplementation reduce neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR)?
2. Does hydroxytyrosol supplementation lower systolic and/or diastolic blood pressure?
3. Does hydroxytyrosol supplementation increase superoxide dismutase (SOD) levels?

Researchers will compare a group receiving hydroxytyrosol supplementation to a standard care control group to see if hydroxytyrosol produces superior anti-inflammatory and antioxidant effects.

Participants will:

* Take hydroxytyrosol 10 mg orally once daily for 4 weeks (intervention group) or receive standard antenatal care without hydroxytyrosol (control group).
* Undergo laboratory testing (NLR, MLR, SOD) before and after the intervention.
* Have their blood pressure monitored regularly throughout the study period.

Conditions

  • Hypertension in Pregnancy

Interventions

DIETARY_SUPPLEMENT

Placebo

Placebo oral capsule identical in appearance to hydroxytyrosol supplement, administered once daily for 4 weeks.

DIETARY_SUPPLEMENT

Hydroxytyrosol

Hydroxytyrosol is a natural polyphenol with antioxidant and anti-inflammatory properties, derived from olives. In this study, hydroxytyrosol 10 mg will be administered orally once daily for 4 weeks to assess its effects on blood pressure and inflammatory biomarkers in hypertensive pregnant women.

Sponsors & Collaborators

  • Dr Cipto Mangunkusumo General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
24 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-10
Primary Completion
2025-08-31
Completion
2025-09-30

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07074548 on ClinicalTrials.gov